Dr. Nataliya Uboha is joined by Drs. Philip A. Philip, Jun Gong, Vincent Lam, Michael Gibson, and Farshid Dayyani for a roundtable discussion on the current and future treatment considerations for gastric, GEJ, and esophageal cancers.

In this segment, they delve into the clinical implications of recent trial data on IO in the perioperative and adjuvant setting, exploring real-world questions surrounding the adoption of new standards from the MATTERHORN and CHECKMATE 577 studies, including how to manage patients already in treatment, how PD-L1 status influences decision-making, and more.